Capricor Therapeutics Future Growth

Future criteria checks 5/6

Capricor Therapeutics is forecast to grow earnings and revenue by 67.6% and 53.2% per annum respectively while EPS is expected to grow by 68.4% per annum.

Key information

67.6%

Earnings growth rate

68.4%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	53.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	20 Nov 2024

Recent future growth updates

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Earnings and Revenue Growth Forecasts

NasdaqCM:CAPR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	113	18	-57	-45	6
12/31/2025	38	-40	-72	-61	7
12/31/2024	21	-39	-20	-19	7
9/30/2024	23	-34	-38	-37	N/A
6/30/2024	27	-28	-36	-34	N/A
3/31/2024	27	-24	-33	-31	N/A
12/31/2023	25	-22	-28	-26	N/A
9/30/2023	14	-29	-23	-21	N/A
6/30/2023	9	-29	-21	-18	N/A
3/31/2023	6	-29	-18	-15	N/A
12/31/2022	3	-29	2	5	N/A
9/30/2022	2	-27	4	6	N/A
6/30/2022	N/A	-25	7	9	N/A
3/31/2022	0	-23	9	11	N/A
12/31/2021	0	-20	-18	-17	N/A
9/30/2021	0	-18	-16	-15	N/A
6/30/2021	0	-18	-15	-15	N/A
3/31/2021	0	-17	-13	-12	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-11	-8	-8	N/A
6/30/2020	1	-9	-7	-7	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-9	-9	-9	N/A
6/30/2019	2	-12	-10	-10	N/A
3/31/2019	2	-14	-12	-12	N/A
12/31/2018	2	-15	-14	-14	N/A
9/30/2018	1	0	-13	-13	N/A
6/30/2018	2	2	N/A	-13	N/A
3/31/2018	2	2	N/A	-13	N/A
12/31/2017	3	2	N/A	-14	N/A
9/30/2017	3	-14	N/A	-15	N/A
6/30/2017	4	-17	N/A	-14	N/A
3/31/2017	4	-18	N/A	-15	N/A
12/31/2016	4	-19	N/A	-14	N/A
9/30/2016	4	-18	N/A	-15	N/A
6/30/2016	5	-15	N/A	-16	N/A
3/31/2016	5	-14	N/A	-13	N/A
12/31/2015	6	-13	N/A	-11	N/A
9/30/2015	6	-11	N/A	-9	N/A
6/30/2015	6	-10	N/A	-8	N/A
3/31/2015	6	-8	N/A	-12	N/A
12/31/2014	5	-6	N/A	1	N/A
9/30/2014	3	-9	N/A	3	N/A
6/30/2014	2	-9	N/A	1	N/A
3/31/2014	1	-9	N/A	6	N/A
12/31/2013	1	-9	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CAPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CAPR is expected to become profitable in the next 3 years.

Revenue vs Market: CAPR's revenue (53.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: CAPR's revenue (53.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CAPR's Return on Equity is forecast to be high in 3 years time

Capricor Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 28% to US$25.40

Forecast to breakeven in 2026

Consensus revenue estimates increase by 21%

Consensus revenue estimates fall by 16%

Consensus revenue estimates increase by 24%, EPS downgraded

Forecast breakeven date pushed back to 2026

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

New major risk - Shareholder dilution

Capricor Therapeutics, Inc. Intends to File A Biologics License Application

Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.004 million.

Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Price target increased by 28% to US$25.40

Forecast to breakeven in 2026

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd.

Consensus revenue estimates fall by 16%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

New major risk - Financial position

Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Profitability

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 24%, EPS downgraded

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 41%

Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

New major risk - Financial position

Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates fall by 51%

New minor risk - Market cap size

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors

New minor risk - Share price stability

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors

Capricor Therapeutics, Inc Announces Board Changes

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Business Officer exercised options and sold US$51k worth of stock

Independent Director notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

Forecast to breakeven in 2025

Now 26% undervalued after recent price drop

Consensus revenue estimates increase by 146%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Forecast to breakeven in 2024